Heart failure drug JARDIANCE® passes Long-Term safety check in japan

NCT ID NCT05262764

Completed Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study monitored 1200 Japanese patients with chronic heart failure who were prescribed JARDIANCE® (empagliflozin) for the first time. Researchers tracked side effects, deaths, and hospitalizations over the long term to see how the drug performs in everyday use. The goal was to confirm the drug's safety and effectiveness outside of controlled clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: empagliflozin (JARDIANCE®)
What this could lead to: If results are positive, this could confirm that JARDIANCE® is safe and effective for long-term heart failure management in Japanese patients.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to non-Japanese populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congestive heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE

Contacts and locations

Locations

Nippon Boehringer Ingelheim Co., Ltd.

Tokyo, 1416017, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.